Novartis (VTX:NOVN) received a CHF 100 price objective from analysts at Bank of America in a research note issued to investors on Monday, September 10th. The brokerage presently has a “buy” rating on the stock. Bank of America’s price objective suggests a potential upside of 27.58% from the stock’s current price.
Several other research analysts have also weighed in on NOVN. Credit Suisse Group set a CHF 80 price objective on shares of Novartis and gave the stock a “neutral” rating in a report on Monday, May 28th. HSBC set a CHF 79 price objective on shares of Novartis and gave the stock a “neutral” rating in a report on Tuesday, May 29th. JPMorgan Chase & Co. set a CHF 84 price objective on shares of Novartis and gave the stock a “neutral” rating in a report on Monday, June 4th. Barclays set a CHF 70 price target on shares of Novartis and gave the company a “sell” rating in a report on Monday, June 18th. Finally, Deutsche Bank set a CHF 89 price target on shares of Novartis and gave the company a “neutral” rating in a report on Wednesday, June 27th. Eleven equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of CHF 88.86.
Shares of NOVN stock traded up CHF 0.34 during trading hours on Monday, hitting CHF 78.38. 11,210,000 shares of the company were exchanged, compared to its average volume of 5,980,000. Novartis has a 1 year low of CHF 72.45 and a 1 year high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Featured Story: Understanding Price to Earnings Ratio (PE)
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.